• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).

作者信息

Jensen Jesper, Omar Massar, Kistorp Caroline, Tuxen Christian, Gustafsson Ida, Køber Lars, Gustafsson Finn, Faber Jens, Forman Julie L, Møller Jacob E, Schou Morten

机构信息

Department of Cardiology (J.J., M.S.), Herlev and Gentofte University Hospital, Denmark.

Department of Clinical Medicine (J.J., C.K., L.K., F.G., J.F., M.S.), University of Copenhagen, Denmark.

出版信息

Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.

DOI:10.1161/CIRCULATIONAHA.120.053463
PMID:34061581
Abstract
摘要

相似文献

1
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).恩格列净治疗心力衰竭的代谢效应：一项随机、双盲、安慰剂对照试验（Empire HF Metabolic）
Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.
2
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).恩格列净对射血分数降低的心力衰竭合并 2 型糖尿病或糖尿病前期患者左心室容积的影响（SUGAR-DM-HF）。
Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.
3
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.恩格列净对心力衰竭患者肺动脉压的影响：EMBRACE-HF试验结果
Circulation. 2021 Apr 27;143(17):1673-1686. doi: 10.1161/CIRCULATIONAHA.120.052503. Epub 2021 Feb 8.
4
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.恩格列净对心力衰竭患者估算细胞外液量、估算血浆量和肾小球滤过率的影响（Empire HF Renal）：一项双盲、随机、安慰剂对照试验的预先指定亚研究。
Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22.
5
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.恩格列净在射血分数降低的非糖尿病心力衰竭患者中的随机临床试验。
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. doi: 10.1016/j.jacc.2020.11.008. Epub 2020 Nov 13.
6
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).恩格列净治疗射血分数降低的心力衰竭患者的随机临床试验（Empire HF）。
Trials. 2019 Jun 21;20(1):374. doi: 10.1186/s13063-019-3474-5.
7
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.恩格列净对伴或不伴糖尿病的心力衰竭患者心血管和肾脏结局的影响：来自 EMPEROR-Reduced 试验的结果。
Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11.
8
Dapagliflozin (Farxiga) - a new indication for heart failure.达格列净（安达唐）——心力衰竭的新适应症。
Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-103.
9
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.恩格列净治疗老年肥胖且心力衰竭风险增加患者的研究方案：Empire Prevent 试验项目。
Am Heart J. 2024 May;271:84-96. doi: 10.1016/j.ahj.2024.02.005. Epub 2024 Feb 15.
10
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?EMPA-TROPISM 试验（ATRU-4）的原理和设计：恩格列净的“心脏获益”是否与其降血糖活性无关？
Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95. doi: 10.1007/s10557-018-06850-0.

引用本文的文献

1
New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.钠-葡萄糖协同转运蛋白2抑制剂对心肾的益处及miR-30家族协同作用的新见解。
Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov.
2
Empagliflozin in the treatment of heart failure.恩格列净治疗心力衰竭。
Future Cardiol. 2024 Apr 25;20(5-6):251-261. doi: 10.1080/14796678.2024.2360818. Epub 2024 Jun 12.
3
Adverse plasma branched-chain amino acid profile mirrors fatty muscle degeneration in diabetic heart failure patients.
糖尿病心力衰竭患者的不良血浆支链氨基酸谱反映了肌肉脂肪变性。
ESC Heart Fail. 2024 Oct;11(5):2941-2953. doi: 10.1002/ehf2.14872. Epub 2024 May 29.
4
Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.恩格列净用于心力衰竭合并2型糖尿病患者：与其他钠-葡萄糖协同转运蛋白2抑制剂比较的临床证据及潜在机制
J Cardiovasc Transl Res. 2023 Apr;16(2):327-340. doi: 10.1007/s12265-022-10302-4. Epub 2022 Aug 15.
5
Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.在接受卡格列净治疗的 2 型糖尿病合并心力衰竭患者中，血清胰岛素水平与心力衰竭相关参数的相关性：随机 CANDLE 试验的事后分析。
Cardiovasc Diabetol. 2022 Aug 8;21(1):151. doi: 10.1186/s12933-022-01589-3.
6
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).恩格列净对心力衰竭患者生长分化因子 15 的影响：一项随机对照试验（Empire HF Biomarker）。
Cardiovasc Diabetol. 2022 Feb 27;21(1):34. doi: 10.1186/s12933-022-01463-2.